- Home
- ANAB vs DAVE Comparison
ANAB vs DAVE Comparison
Compare ANAB & DAVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- DAVE
- Stock Information
- Founded
- ANAB 2005
- DAVE 2017
- Country
- ANAB United States
- DAVE United States
- Employees
- ANAB N/A
- DAVE N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- DAVE Retail: Computer Software & Peripheral Equipment
- Sector
- ANAB Health Care
- DAVE Technology
- Exchange
- ANAB Nasdaq
- DAVE Nasdaq
- Market Cap
- ANAB 759.5M
- DAVE 795.6M
- IPO Year
- ANAB 2017
- DAVE N/A
- Fundamental
- Price
- ANAB $13.04
- DAVE $97.81
- Analyst Decision
- ANAB Buy
- DAVE Strong Buy
- Analyst Count
- ANAB 11
- DAVE 6
- Target Price
- ANAB $42.67
- DAVE $96.50
- AVG Volume (30 Days)
- ANAB 775.9K
- DAVE 480.7K
- Earning Date
- ANAB 11-05-2024
- DAVE 11-12-2024
- Dividend Yield
- ANAB N/A
- DAVE N/A
- EPS Growth
- ANAB N/A
- DAVE N/A
- EPS
- ANAB N/A
- DAVE 3.12
- Revenue
- ANAB $57,172,000.00
- DAVE $319,355,000.00
- Revenue This Year
- ANAB $233.68
- DAVE $34.76
- Revenue Next Year
- ANAB N/A
- DAVE $19.52
- P/E Ratio
- ANAB N/A
- DAVE $31.36
- Revenue Growth
- ANAB 282.17
- DAVE 30.00
- 52 Week Low
- ANAB $13.00
- DAVE $7.73
- 52 Week High
- ANAB $41.31
- DAVE $108.50
- Technical
- Relative Strength Index (RSI)
- ANAB 27.77
- DAVE 59.92
- Support Level
- ANAB $15.11
- DAVE $81.00
- Resistance Level
- ANAB $16.74
- DAVE $108.50
- Average True Range (ATR)
- ANAB 1.48
- DAVE 9.17
- MACD
- ANAB -0.31
- DAVE -0.67
- Stochastic Oscillator
- ANAB 0.31
- DAVE 61.14
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit, and finding side gigs.